RO7079901

DRUG3 trials

Sponsors

Hoffmann-La Roche

Conditions

Healthy VolunteersRenal ImpairmentUrinary Tract Infections

Phase 1

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of RO7079901 and the Combination of RO7079901 With Meropenem in Adult Healthy Volunteers

CompletedNCT02972255

Hoffmann-La RocheHealthy Volunteers

Start: 2016-10-31End: 2017-03-24Updated: 2017-05-19

A Study to Investigate the Effect of Renal Function and Hemodialysis on the Pharmacokinetics (PK) of RO7079901

CompletedNCT02975388

Hoffmann-La RocheRenal Impairment

Start: 2016-12-20End: 2017-07-06Updated: 2017-12-11

A Study to Investigate the Pharmacokinetics of RO7079901 and Meropenem in Participants With a Complicated Urinary Tract Infection

CompletedNCT03174795

Hoffmann-La RocheUrinary Tract Infections

Start: 2017-07-11End: 2017-12-16Updated: 2018-05-15

Related Papers

Safety and Pharmacokinetic Characterization of Nacubactam, a Novel β-Lactamase Inhibitor, Alone and in Combination with Meropenem, in Healthy Volunteers.

2020-04-2138 citations